NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2003
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Mechanism of Action
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Clinical Trials (1)
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
Started Sep 2005
267 enrolled
Cataract
Loss of Exclusivity
LOE Date
Nov 24, 2027
21 months away
Patent Expiry
Nov 24, 2027
Patent Records (2)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8008338 | May 24, 2027 | SubstanceProduct | U-1181 |
| 8008338*PED | Nov 24, 2027 | — |